RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Massachusetts General Hospital · Memorial Sloan Kettering Cancer Center · +8 more institutions
Abstract
Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with this transformation remain unknown. Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC. Further, increased neuroendocrine marker and decreased EGFR…
Citation impact
- FWCI
- 27.41
- Percentile
- 100%
- References
- 39
Authors
27- MJMatthew J. NiederstCorresponding
Massachusetts General Hospital
- LVLecia V. Sequist
Massachusetts General Hospital
- JTJohn T. Poirier
Memorial Sloan Kettering Cancer Center
- CHCraig H. Mermel
Broad Institute, Center for Cancer Research, Analysis Group (United States)
- ELElizabeth L. Lockerman
Massachusetts General Hospital
Topics & keywords
- Epidermal growth factor receptor
- Cancer research
- Lung cancer
- Mutant
- Phenotype
- Mutation
- Small Cell Lung Carcinoma
- Tyrosine kinase
- Good health and well-being